MedTrace Logo

Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection

NCT04372017 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2021-12-10

Study results available
· View outcomes & findings →

Summary

This is a prospective, double-blind, randomized, placebo-controlled study in two distinct cohorts to evaluate the efficacy and safety of hydroxychloroquine in the prevention of COVID-19 infection.

Conditions

Interventions

DRUG

Hydroxychloroquine

Participants randomized to hydroxychloroquine will take 800mg on day 1 followed by 400mg on days 2-5.

DIETARY_SUPPLEMENT

Vitamin D

Participants randomized to placebo will take IU1600 on day 1 and IU 800 on days 2-5.

Sponsors & Collaborators

  • Sanford Health

    lead OTHER

Principal Investigators

  • Susan Hoover, MD · Sanford Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-14
Primary Completion
2021-06-04
Completion
2021-06-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04372017 on ClinicalTrials.gov